Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 19 March 2004:
Vol. 303. no. 5665, pp. 1796 - 1799
DOI: 10.1126/science.303.5665.1796
Prev | Table of Contents | Next

News

Surviving the Blockbuster Syndrome

Robert F. Service

New technologies have sent drug company R&D costs soaring, but with no corresponding rise as yet in the number of new drugs. Executives are talking about mergers, reorganization, and other ways to kick-start their production engines.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Three-dimensional cellular microarray for high-throughput toxicology assays.
M.-Y. Lee, R. A. Kumar, S. M. Sukumaran, M. G. Hogg, D. S. Clark, and J. S. Dordick (2008)
PNAS 105, 59-63
   Abstract »    Full Text »    PDF »
Pharmacogenomics: Bench to Bedside.
R. Weinshilboum and L. Wang (2006)
Focus 4, 431
   Abstract »    Full Text »    PDF »
Evidence-based toxicology: a comprehensive framework for causation.
P. S Guzelian, M. S Victoroff, N C. Halmes, R. C James, and C. P Guzelian (2005)
Human and Experimental Toxicology 24, 161-201
   Abstract »    PDF »
Drug Discovery, CAM and Natural Products.
E. L. Cooper (2004)
Evid. Based Complement. Altern. Med. 1, 215-217
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)